Skip to main content
Xuying Pei on Muck Rack

Xuying Pei

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xuying

Contact Xuying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia

|
By Meng Lv, Hongli Zheng, Wenbo Chen, Yutong Bao, Zhengli Xu, Lijuan Hu, Zhe Wan, Xueqiang Zhao, Zhixiao Zhou, Xin Lin, Xiaojun Huang, Jiasheng Wang, Xiangyu Zhao, Xuying Pei, Yiyang Ding
| Nature Verified
Abstract Acute myeloid leukemia (AML) is a rapidly progressive malignancy with poor prognosis. To date, chimeric antigen receptor (CAR) T-cell therapy in AML has been limited by the lack of antigens with high specificity for AML cells. Here, we developed a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting LILRB4, an immunosuppressive receptor highly expressed on monocytic AML blasts but not on hematopoietic stem cells.
Open in Who Shared Issue with article?
See all 1 articles